Inherent level of circKCNN2 in HCC cells predisposes anti‐tumor effect of lenvatinib possibly because both circKCNN2 and lenvatinib repress the expression of FGFR4. This evidence concerns the gene FGFR4 and hepatocellular carcinoma.